77 related articles for article (PubMed ID: 23858037)
1. Phase II, randomized, open-label study of pegfilgrastim-supported VDC/IE chemotherapy in pediatric sarcoma patients.
Spunt SL; Irving H; Frost J; Sender L; Guo M; Yang BB; Dreiling L; Santana VM
J Clin Oncol; 2010 Mar; 28(8):1329-36. PubMed ID: 20142595
[TBL] [Abstract][Full Text] [Related]
2. Filgrastim biosimilar (EP2006): A review of 15 years' post-approval evidence.
Gascón P; Harbeck N; Rapoport BL; Anderson R; Brueckmann I; Howe S; Aapro M
Crit Rev Oncol Hematol; 2024 Apr; 196():104306. PubMed ID: 38401695
[TBL] [Abstract][Full Text] [Related]
3. Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study.
Nahon S; Rastkhah M; Ben Abdelghani M; Soumoudronga RF; Gasnereau I; Labourey JL
Support Care Cancer; 2016 May; 24(5):1991-1998. PubMed ID: 26507190
[TBL] [Abstract][Full Text] [Related]
4. An open-label, dose-ranging study of Rolontis, a novel long-acting myeloid growth factor, in breast cancer.
Vacirca JL; Chan A; Mezei K; Adoo CS; Pápai Z; McGregor K; Okera M; Horváth Z; Landherr L; Hanslik J; Hager SJ; Ibrahim EN; Rostom M; Bhat G; Choi MR; Reddy G; Tedesco KL; Agajanian R; Láng I; Schwartzberg LS
Cancer Med; 2018 May; 7(5):1660-1669. PubMed ID: 29573207
[TBL] [Abstract][Full Text] [Related]
5. Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study).
Aapro M; Ludwig H; Bokemeyer C; Gascón P; Boccadoro M; Denhaerynck K; Krendyukov A; Gorray M; MacDonald K; Abraham I
Ann Oncol; 2016 Nov; 27(11):2039-2045. PubMed ID: 27793849
[TBL] [Abstract][Full Text] [Related]
6. Effect of lithium on chemotherapy-induced neutropenia in Egyptian breast cancer patients; a prospective clinical study.
ELKasar AO; Hussien FZ; Abdel-Hamied HE; Saleh IG; Mahgoup EM; El-Arabey AA; Abd-Allah AR
Cancer Chemother Pharmacol; 2024 Jun; 93(6):541-554. PubMed ID: 38324036
[TBL] [Abstract][Full Text] [Related]
7. A whole-body circulatory neutrophil model with application to predicting clinical neutropenia from in vitro studies.
Chen W; Boras B; Sung T; Hu W; Spilker ME; D'Argenio DZ
CPT Pharmacometrics Syst Pharmacol; 2021 Jul; 10(7):671-683. PubMed ID: 33793091
[TBL] [Abstract][Full Text] [Related]
8. Clinical experience with Zarzio® in Europe: what have we learned?
Gascón P; Tesch H; Verpoort K; Rosati MS; Salesi N; Agrawal S; Wilking N; Barker H; Muenzberg M; Turner M
Support Care Cancer; 2013 Oct; 21(10):2925-32. PubMed ID: 23903799
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial of Bacteroides fragilis 839 on preventing chemotherapy-induced myelosuppression and gastrointestinal adverse effects in breast cancer patients.
Zeng T; Deng YH; Lin CH; Chen XX; Jia HX; Hu XW; Xia T; Ling Y; Zhang LH; Cao TF
Asia Pac J Clin Nutr; 2024 Mar; 33(1):23-32. PubMed ID: 38494684
[TBL] [Abstract][Full Text] [Related]
10. Clinical evaluation of the bispecific antibody MDX-H210 (anti-Fc gamma RI x anti-HER-2/neu) in combination with granulocyte-colony-stimulating factor (filgrastim) for treatment of advanced breast cancer.
van Ojik HH; Repp R; Groenewegen G; Valerius T; van de Winkel JG
Cancer Immunol Immunother; 1997; 45(3-4):207-9. PubMed ID: 9435875
[No Abstract] [Full Text] [Related]
11. Association between Concomitant Use of Hydrochlorothiazide and Adverse Chemotherapy-Related Events among Older Women with Breast Cancer Treated with Cyclophosphamide.
Hsu CD; Hinton SP; Reeder-Hayes KE; Sanoff HK; Lund JL
Cancer Epidemiol Biomarkers Prev; 2020 Feb; 29(2):520-523. PubMed ID: 31871107
[TBL] [Abstract][Full Text] [Related]
12. The Relationship between Common Genetic Markers of Breast Cancer Risk and Chemotherapy-Induced Toxicity: A Case-Control Study.
Dorling L; Kar S; Michailidou K; Hiller L; Vallier AL; Ingle S; Hardy R; Bowden SJ; Dunn JA; Twelves C; Poole CJ; Caldas C; Earl HM; Pharoah PD; Abraham JE
PLoS One; 2016; 11(7):e0158984. PubMed ID: 27392074
[TBL] [Abstract][Full Text] [Related]
13. Filgrastim Use in the Treatment of Azathioprine-Induced Myelosuppression Toxicity After Prescription Error in the Feline.
Klar L
J Am Anim Hosp Assoc; 2024 May; 60(3):105-108. PubMed ID: 38662994
[TBL] [Abstract][Full Text] [Related]
14. Comparison between filgrastim biosimilar and filgrastim original for the management of neutropenia after salvage chemotherapy for malignant lymphoma.
Shimano R; Yamamoto H; Nasu I; Kashiwamura Y; Yamamoto G; Uchida N; Taniguchi S; Hayashi M; Ito T
Int J Hematol; 2022 Dec; 116(6):856-862. PubMed ID: 35976562
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of FSK0808, filgrastim biosimilar: a multicenter, non-randomized study in Japanese patients with breast cancer.
Sagara Y; Sato K; Fukuma E; Higaki K; Mizutani M; Osaki A; Takano T; Tokuda Y; Ohno S; Masuda N; Suzuki M; Saeki T
Jpn J Clin Oncol; 2013 Sep; 43(9):865-73. PubMed ID: 23858037
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.
Blackwell K; Gascon P; Krendyukov A; Gattu S; Li Y; Harbeck N
Ann Oncol; 2018 Jan; 29(1):244-249. PubMed ID: 29091995
[TBL] [Abstract][Full Text] [Related]
17. Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.
Blackwell K; Semiglazov V; Krasnozhon D; Davidenko I; Nelyubina L; Nakov R; Stiegler G; Singh P; Schwebig A; Kramer S; Harbeck N
Ann Oncol; 2015 Sep; 26(9):1948-1953. PubMed ID: 26122726
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
Puértolas I; Frutos Pérez-Surio A; Alcácera MA; Andrés R; Salvador MDT
Eur J Clin Pharmacol; 2018 Mar; 74(3):315-321. PubMed ID: 29152672
[TBL] [Abstract][Full Text] [Related]
19. Pegfilgrastim administered once per cycle reduces incidence of chemotherapy-induced neutropenia.
Crawford J
Drugs; 2002; 62 Suppl 1():89-98. PubMed ID: 12479597
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
